The results of experiments in vivo and in AD patients indicate that, being in the blood plasma or in the cerebrospinal fluid, transthyretin is able to prevent the formation of Aβ-based amyloid fibrils (Figure 2D) [82]. Here, TTR is linked to Alzheimer disease.